New Era Helium (NEH)

Founded in 2023, New Era Helium, Inc. (NEH) is a helium exploration and production company operating 137,000 acres in New Mexico, with 1.5 billion cubic feet (BCF) of helium reserves. Our goal is to secure 1% of the North American helium market, aiming to be a key player in the distribution of helium across North America.  With plant construction underway and completion expected in Q2 2025, New Era Helium is strategically positioned to generate three revenue streams—helium, natural gas, and natural gas liquids—and to become a strong platform for consolidating start-up exploration and midstream players, driving growth and operational synergy.

Abacus Life, Inc. operates as an alternative asset manager and market maker in the United States. It operates through three segments: Portfolio Servicing, Active Management, and Originations. The Portfolio Servicing segment provides policy services to customers on a contract basis. The Active Management segment is involved in buying, selling, and trading policies, as well as maintaining policies until receipt of death benefits. The Originations segment originates life insurance policy settlements between investors or buyers, and the sellers, who is often the original policy owner. The company sells its products through financial advisor or agent, direct to consumer, and traditional life settlements intermediaries. Abacus Life, Inc. was founded in 2004 and is headquartered in Orlando, Florida.

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Actelis Networks, Inc.

Secure Connectivity Solutions for Fast Expansion of IoT Networks

Actinium Pharmaceuticals, Inc.

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML), which Actinium is seeking a potential strategic partner for in the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

AgriForce AGRI

ABOUT AGRIFORCE AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) is dedicated to revolutionizing agriculture and food systems through innovative technology and sustainable practices. By integrating intellectual property, advanced technology, and deep industry expertise, AgriFORCE delivers solutions that drive value for shareholders and the communities it serves. Learn more at www.agriforcegs.com.

Ai Education Systems

Breakthrough artificial intelligence (A.I.) for teaching any topic, to any user, and speak to them in their native language. Creating the ultimate ‘Super Teachers’ .

Alico, Inc.

Alico, Inc. is a holding company, which engages in the operations of agriculture, land management, and natural resources. It operates through the Alico Citrus, and Land Management and Other Operations segments. The Alico Citrus segment cultivates citrus trees to produce citrus for delivery to the processed and fresh citrus markets. The Land Management and Other Operations segment offers land leasing for recreational and grazing purposes, conservation, and mining activities. The company was founded on February 29, 1960 and is headquartered in Fort Myers, FL

AsiaFIN Holdings Corp ASFH

ASFH is a financial ecosystem enabler based out of Malaysia with customers in 8 countries in Asia. ASFH is involved in fintech, regtech and RPA. ASFH plans to expand into the Middleeast and to the USA in 2025- 2026

Better Home & Finance (BETR)

Since 2017, Better Home & Finance Holding Company (NASDAQ: BETR; BETRW) has leveraged its industry-leading technology platform, Tinman™, to fund more than $100 billion in mortgage volume. Tinman™ allows customers to see their rate options in seconds, get pre-approved in minutes, lock in rates and close their loan in as little as three weeks. Better’s mortgage offerings include GSE-conforming mortgage loans, FHA and VA loans, and jumbo mortgage loans. Better launched its “One Day Mortgage” program in January 2023, which allows eligible customers to go from click to Commitment Letter within 24 hours. Better was named Best Online Mortgage Lender by Forbes and Best Mortgage Lender for Affordability by WSJ in 2023, ranked #1 on LinkedIn’s Top Startups List for 2021 and 2020, #1 on Fortune’s Best Small and Medium Workplaces in New York, #15 on CNBC’s Disruptor 50 2020 list, and was listed on Forbes FinTech 50 for 2020. Better serves customers in all 50 US states and the United Kingdom.

BIO-key International, Inc.

BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

biomerica BMRA

About Biomerica (NASDAQ: BMRA) Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development. About inFoods® The inFoods IBS test is designed to assess a patient’s above normal immunoreactivity to specific foods utilizing a simple finger-stick blood sample. Instead of difficult to manage broad dietary restrictions, physicians can now use the inFoods IBS information to make targeted, patient-specific recommendations about trigger foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The inFoods IBS test and clinical outcomes were studied at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The clinical results for improvement in the Abdominal Pain Intensity (API) responder endpoint of >30% reduction in pain, for IBS patients in the treatment diet arm was greater than patients in the placebo diet arm (p-value of 0.0246). The improvement for patients in the treatment arm versus the placebo arm is considered clinically significant and for certain endpoints is similar and, in some cases, better than the current drugs in the market. Further information about Biomerica’s patented inFoods® Technology Platform can be found at www.infoodsibs.com

BitFuFu Inc FUFU

BitFuFu is a fast-growing digital asset mining service and world-leading cloud-mining service provider. BitFuFu received early investment from Bitmain, a world-leading digital asset mining hardware manufacturer, and remains Bitmain's sole strategic partner in the cloud mining space. BitFuFu is dedicated to fostering a secure, compliant, and transparent blockchain infrastructure, providing a variety of stable and intelligent digital asset mining solutions to a global customer base. Leveraging its expanding global mining facility network and strategic partnership with Bitmain, BitFuFu enables institutional customers and digital asset enthusiasts to mine digital assets efficiently.

Citius Pharmaceuticals, Inc. CTXR

Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR™, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs.

Corero Network PLC

Corero Network Security is the leading DDoS protection specialist listed on the AIM market of the London Stock Exchange (AIM: CNS) as well as the US OTC Market (OTCQX: DDoSF). Corero provides best-in-class automatic detection and protection DDoS solutions with network visibility, analytics, and reporting tools. Corero’s technology protects against external and internal DDoS threats in complex edge and subscriber environments, ensuring internet service availability. Headquartered in London, Corero has operational centers in Massachusetts, USA, and Edinburgh, UK.

Duos Technologies Group, Inc. DUOT

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiaries, Duos Technologies, Inc., Duos Edge AI, Inc., and Duos Energy Corporation designs, develops, deploys, and operates intelligent technology solutions for Machine Vision and Artificial Intelligence (“AI”) applications including real-time analysis of fast-moving vehicles, Edge Data Centers and power consulting. For more information, visit www.duostech.com,  www.duosedge.ai, and www.duosenergycorp.com.

Ecora Resources

Ecora Resources is a leading royalty company focused on supporting the supply of commodities essential to creating a sustainable future. Our vision is to be globally recognized as the royalty company of choice synonymous with commodities that support a sustainable future by continuing to grow and diversify our royalty portfolio in line with our strategy. We will achieve this through building a diversified portfolio of scale over high quality assets that drives low volatility earnings growth and shareholder returns. Our strategy is to acquire royalties and streams over low-cost operations and projects with strong management teams, in well-established mining jurisdictions. Our portfolio has been reweighted to provide material exposure to this commodity basket and we have successfully transitioned from a coal orientated royalty business in 2014 to one that by 2026 will be coal free and comprised of over 90% exposure to commodities that support a sustainable future. The fundamental demand outlook for these commodities is highly attractive and expected to result in substantial price increases over the medium to long term, which should significantly increase the value of our royalty portfolio.

ESG Inc.

ESG Inc. (“ESG” or the “Company” or “We”) was incorporated in July 2021 as a Nevada corporation and is headquartered at Kennett Square, being traded on OTC Markets with the sym- bol of ESGH as a public company to develop and operate sustainable plant based food and in- gredients production and distribution with the substantial experience of its management team, the board of directors and the advisory board, including expertise and relationships in the industry of mushroom, agriculture and food in the world and the capital markets in the States.

FendX Technologies Inc

At the intersection of healthcare and advanced materials, FendX is dedicated to advancing products under development using its innovative nanotechnology to keep surfaces safe from contamination. Products in development include a film and nano-particle solution that have been shown to significantly reduce the adhesion and transmission of bacteria and viruses. REPELWRAP™ film is currently in real-world beta-testing and the solution is in the formulation phase. FendX is also using its novel nanotechnology to develop nano-coated catheter protypes to minimize blood clots and bacterial biofilm formation. The Company conducts R&D in collaboration with industry-leading partners, including McMaster University, and has exclusive worldwide licenses to its nanotechnology from McMaster. FendX is also actively pursuing additional in-licensing and acquisition opportunities to expand its infection disease control product portfolio and enhance its impact in protecting surfaces. Recently, FendX signed a letter of intent (LOI) to acquire certain intellectual property as well as enter into a supply agreement for an eco-friendly foam pad that offers a sustainable surface cleaning solution and future potential as a wound care drug delivery platform.

Findpro Group Inc

Wilmington, Delaware--(Newsfile Corp. - December 29, 2022) - Remote hiring company FindPro Group, Inc. has announced that within the next 12 weeks, it will be releasing a full-service app that will serve as an on-demand platform allowing tech companies to hire in real time. Tech talent as well will have the full spectrum of FindPro's services right in their pocket, allowing qualified professionals to find jobs more quickly than ever before.

GreenRise Foods

Controlled Environment Agriculture company that produces over 20 million pounds of tomatoes and mini sweet peppers annually. The fresh produce is sold to retailers such as Costco.

Healthy Choice Wellness Corp HCWC

Healthy Choice Wellness Corp (NYSEAM: HCWC) is a U.S. based publicly traded company specializing in providing consumers with healthier alternatives to everyday lifestyle choices. Local. Organic. Fresh. Three words that define Healthy Choice Markets! Under its wholly owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets II, LLC, Healthy Choice Markets III, LLC, Healthy Choice Markets IV, LLC, Healthy Choice Markets V, LLC and Healthy Choice Markets VI, LLC, HCWC owns and operates Ada's Natural Market, a. full-service grocery store, serving Fort Myers, FL, along with three (3) Paradise Health & Nutrition locations in the greater Melbourne, FL area, Mother Earth’s Storehouse in Hudson Valley, NY, eight (8) Green’s Natural Foods in New York and New Jersey States, Ellwood Thompson’s Local Market in Richmond, VA, and our newly acquired five (5) GreenAcres Market in Kansas and Oklahoma, all serving their respective local communities.

ImmunoPrecise Antibodies IPA

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Impact Biomedical Inc. IBO

Impact BioMedical Inc.(NYSE American: IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Issuer Direct Corp

Issuer Direct is a leading communications company, providing solutions for both Public Relations and Investor Relations Professionals for over 16 years. Our comprehensive solutions are used by thousands of customers from emerging startups to multi-billion-dollar global brands, ensuring their most important moments are reaching the right audiences, via our industry-leading newswire, IR website solutions, events technology, and compliance solutions. For more information, please visit www.issuerdirect.com

Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs.

Nabu

Nabu streamlines prospectus drafting and post-listing regulatory disclosure with artificial intelligence. It helps underwriters, issuers and listed companies automate manual tasks in S-1, 10-K, 10-Q and other SEC regulatory material 75% faster. Nabu is the first AI-powered workspace that helps companies transforms data into narrative-style prospectuses and filings, tailored to each company and aligned with industry standards. Built by technologists and lawyers at top firms like Skadden, Morgan Lewis, Wise and Herbert Smith Freehills, we are backed by venture capitalists with a current seed-round valuation of 15M.

NANO Nuclear Energy Inc. (NNE)

NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable microreactor technology, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S.  Led by a world-class nuclear engineering team, NANO Nuclear's products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.  Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America.  HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry.  NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear™s developing micronuclear reactor technology in space. NNS is focusing on applications such as power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS™ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon™s surface.

NanoViricides, Inc (NNVC)

NanoViricides, Inc (NYSE ticker: NNVC) is a Phase II-ready, clinical stage company developing broad spectrum, anti-viral therapeutics (not vaccines) to treat and potentially cure viral diseases using its patented nanotechnology that is effective even as the virus mutates, unlike today's vaccines, antibodies and small chemicals. NanoViricides, Inc has a fully-owned, GMP-compliant manufacturing facility in Shelton, CT with capability to produce multi-Kg quantities of active components that are sufficient for clinical trial supply; ie. no reliance on external CMOs! This pre-revenue Company is at a major inflection point in Market Valuation because NV-387, the Company lead drug, has just completed Phase I human clinical studies demonstrating excellent safety and tolerability. The official report is imminent. As such, we are Phase II-ready, working on: advancing NV-387 into Phase II clinical trials for MPox in Central Africa; progressing NV-387 towards filing an IND with USA and India Regulators for Phase II clinical trials for the indication of RSV infection in infants and children and a Phase II clinical trial for severe acute respiratory viral infections. Any investment in the company now would therefore be expected to deliver a high return on investment over the coming 5 years. A similar increase in Valuation is expected to occur every time the Company achieves subsequent milestones (eg. Phase III clinical trials) on the road to commercialization of its technology. Our drugs are predicted to remain effective even as viruses mutate and variants emerge because our drugs copy the unique receptor site on cells where a particular virus lands, and this receptor site does NOT change even when the virus mutates. The virus and its variants bind to our drugs decoy receptor site, is engulfed by our shape-shifting drug, and cannot replicate or infect other cells. The Company's lead drug NV-387 is effective against RSV, COVID, M-pox/small pox, and the FLU which are currently multi-billion markets. NV-387 is available as an oral medication, an injection, an infusion, and as a solution for direct inhalation into lungs. Also, patients with a viral infection often have a compromised immune system, so it is noteworthy that our nanomachine does not rely on the patients immune system to cure the viral infection, something that limits most current drugs.This opens up pediatric and geriatric market segments as well as treatments for all levels of disease severity, from out-patient to severely ill hospitalized patients. The potential market size of the above indications alone is well in excess of $10 billion of which NV-387 aims to get a fair share, and which is a small percentage of the global antiviral market size in 2023 estimated at $62 billion, growing to $90 billion by 2033! Any investment in NNVC at this time would accelerate progress towards Phase II clinical trials, the achievement of which would lead to a step jump in Market Valuation of the company and attract collaboration & licensing opportunities with big pharma. Historically, antiviral drug companies with a Phase II asset have been able to generate multi-billion licensing revenues for such one-off drugs stemming from platform technologies or attract acquisition of such assets. For investors interested in the long term prospects of the Company, the strategic plan envisions development of a series of drugs for various families of viruses. The product pipeline includes: NV-HHV-1, our drug candidate for the treatment of Shingles, that as skin cream has completed IND-enabling studies towards Phase I clinical trial. NV-HHV-1 is active against HSV-1 (Cold Sores), HSV-2 (Genital Ulcers), and VZV (Chickenpox, Shingles), because NV-HHV-1 emulates HVEM, the entry port common to herpesviruses. - NV-HIV-1, our anti-HIV/AIDS drug candidate, has shown remarkable effectiveness in animal studies, exceeding that of a triple-drug cocktail. NV-HIV-1 emulates the entry port CD4 that all HIV viruses require. Each of these drugs is expected to alleviate the suffering of generations of patients worldwide from viral diseases and also to generate revenue streams for the Company for decades to come! This pre-revenue Company is at a major inflection point in Market Valuation - a n oppotunity of a lifetime!

Perfect Corp (PERF)

Perfect Corp. (NYSE: PERF), founded in 2015, is the AI powerhouse for beauty and fashion brands. We develop 'Beautiful AI' innovations, including Beauty AI, Skin AI, Fashion AI, and Generative AI SaaS solutions. We lead in assisting top beauty brands in digital transformation, enhancing customer engagement, and driving sales growth while prioritizing sustainability and social responsibilities.

Perfect Moment Ltd. (PMNT)

Perfect Moment Ltd., together with its subsidiaries, owns and operates a fashion brand that offers ski, surf, and activewear collections under the brand name of Perfect Moment in the United States and the United Kingdom. The company offers skiwear, outerwear, swimwear and activewear for women, men, and children. Perfect Moment Ltd. sells its collections directly to customers through e-commerce and to wholesale accounts, as well as through other sales partnerships. The company was founded in 1984 and is based in London, the United Kingdom.

PetVivo Holdings Inc. PETV

About PetVivo Inc: PetVivo Inc. is based in Minneapolis, Minnesota. It is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize medical devices and therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to internally develop and/or in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

Radiance BioPharma

Radiance BioPharma is a privately held biotech company developing Antibody Drug Conjugates Our lead drug, RB-164 we are planning a phase I clinical trial for 2025.

Railtown AI Technologies Inc.

Railtown AI, a Microsoft Partner, has developed a cloud-based Application General Intelligence™ Platform called Conductor. Artificial intelligence and automation that performs tasks as well as streamlining, enhancing, and accelerating Developer Productivity Engineering (DPE) through Speed, Quality, Automation and Best Practices which are the cornerstones and foundation of the Conductor platform.

Reklaim LTD TSXV: MYID OTC: MYIDF

Reklaim Ltd is a privacy-focused data platform empowering consumers to take control of their personal information and earn compensation for its use. Operating in both Canada and the USA, Reklaim offers a transparent, ethical alternative to traditional data collection by allowing users to manage and monetize their data securely. With a commitment to privacy and innovation, Reklaim is reshaping the data economy by prioritizing consumer consent and trust.

Scienture Holdings Inc. (SCNX)

SCIENTURE HOLDINGS, Inc is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the U.S. Enhanced Value: Addressing underserved patients and indications through novel product concepts and innovation Deep Expertise: R&D, Product Development Research and Manufacturing know-how; Unique product pipeline and focused therapeutic area strategy Robust Commercial Operations: Complete suite of Sales and Marketing to include Branding, Promotion, Market Access and Distribution Accomplished leadership and management team: with many years of multidisciplinary experience and deep market knowledge Disruptive Innovation: Significantly lowers drug and health services costs utilizing our proprietary technology platforms Strategic Infrastructure: Well-developed, synergistic divisions ready for growth

Sensus Healthcare, Inc. (SRTS)

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive, and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy photon radiotherapy known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

Silicon Prairie Holdings, Inc

FINTECH powered Investment Banking group with Transfer Agent and Alternative Trading System -- we power up online capital formation publicly and privately

SKYX Platforms Corp. (SKYX)

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 97 U.S. and global patents and patent pending applications. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

Solarbank Corp. (CNSX SUNN)

SolarBank is a Dev-IPP with it’s renewable energy technologies vertically integrated in clean energy generation, transmission, distribution and retail services, creating a Zero Carbon Power Producer in the convergence of electricity grid and transportation grid. As a Dev-IPP, the Company is an established renewable energy platform equipped with end-to-end capabilities and strong growth opportunities across North America. With a pipeline of 1 GW of potential renewable energy projects, such as solar power plants, battery energy storage systems, and EV charging stations, and over 100 solar power plants under IPP management, we originate, develop, finance, engineering, construct, operate, and own renewable energy assets in Canada and the USA.

Soligenix, Inc. SNGX

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We have two areas of focus: 1) a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, psoriasis, oral mucositis, Behçet’s disease, and pediatric Crohn’s disease. 2) a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure and viral disease including Ebola, Marburg and COVID-19.

Soteria Battery Innovation Group

Soteria has technology to make lithium-ion batteries inherently safe. Their technology improves safety, reduces weight, reduces cost, and works with all batteries. Because of this, they are taking it to market with a broad-based licensing business model and have formed a consortium of over 130 companies to support this, including NASA, Mercedes, Daimler Trucks, General Motors, Lenovo and many others.

Tau Lotus Inc

Alternative Energy Mobility Solutions product manufacturing company

Tharimmune, Inc. THAR

Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.

The Metals Company TMC

The Metals Company (Nasdaq: TMC) is a developer of the world’s largest estimated undeveloped resource of battery metals for EVs, and the world’s #1 and #2 largest undeveloped nickel projects as ranked by Mining.com. TMC’s resource in the Clarion Clipperton Zone of the Pacific Ocean contains a very high concentration of nickel, copper, cobalt and manganese, with an estimated resource of 1.6 billion tonnes of nodules, sufficient to support the electrification of 280 million EVs, equivalent to the entire U.S. passenger car fleet. The resource is in the form of polymetallic nodules, which sit unattached on top of the seafloor, so nodule collection requires no blasting, no drilling and no digging. Nodule collection in the Clarion Clipperton Zone was successfully done on a pilot basis by four consortia in the 1970s, including BP, Shell, Rio Tinto, Sumitomo, Lockheed Martin and US Steel. TMC has successfully concluded its own pilot collection trial, lifting 3,000 tonnes to the Hidden Gem vessel in Q4 2022: https://vimeo.com/778303976/28d019f234 TMC's NORI-D area has an SEC S-K 1300 compliant technical report and initial assessment indicating an NPV of $6.8 billion representing just 22% of TMC’s total estimated resource.

TriAgenics Inc

TriAgenics has developed a one-minute treatment for children ages 6 to 12 that prevents wisdom teeth from ever forming. Our one-minute treatment has no recovery time. If you have had your wisdom teeth out, then you know how painful and disruptive this is.

https://trxgold.com/investors/capital-structure/

TRX Gold is growing the Buckreef Gold project in Tanzania, consisting of a low-risk, high-margin open-pit gold mining operation and 2M+ ounces gold in M&I Mineral Resource* at the 16km2 property. The Company completed its 3rd mill expansion in July 2024 and expects to increase its annual gold production guidance for f2025. The Company is also exploration/brownfield drilling with the goal of increasing the Mineral Resource, and has a high-priority program set on its latest discovery, the Stamford Bridge Shear Zone. The Company is self-funded through consistent positive operating cash flow, is debt free and has not had to raise equity since 2021.

Universal Biosensors Inc UBI

Universal Biosensors (UBI) is a global biosensor company and world leader in Point of Use electrochemical sensing. UBI is a Delaware company which is listed on the Australian Stock Exchange (ASX:UBI). UBI has 20 years of experience developing, manufacturing, and delivering accurate and cost-effective analytical results from a portable handheld analyzer using a fingerstick of blood. Our history includes inventing, developing and: 1.partnering (with Johnson&Johnson “LifeScan”) one of the biggest blood glucose testing products (OneTouch Verio) which has sold more than 15 billion tests globally; 2.commercialising two generations of Point of Care coagulation PT/INR products (Xprecia) which monitor a patients PT/INR level within seconds, from a fingerstick sample (sold across 36 countries). US FDA 510(k) and CLIA Waiver approval received for Xprecia Prime in March 2024; 3.commercialising a portable handheld analyzer and 6 assays (Sentia) for the monitoring of six key compounds throughout the wine production process; 4.commercialising a veterinary blood glucose monitoring product (Petrackr) for managing cats and dogs with diabetes. UBI is developing a range of portable Point of Use monitoring products in oncology, fertility, environmental and water sensing including a portable handheld product for water utilities to identify lead and copper pipe infrastructure in drinking water systems.

WiSA Technologies, Inc. WISA

WiSA Technologies, Inc. (NASDAQ: WISA), which is in a definitive agreement to acquire AI, blockchain and Data Web 3.0 IP assets of Data Vault Holdings, Inc.® (“Data Vault”) to form a data technology & licensing company leveraging IP & proprietary HPC software.

ZenaTech ZENA

ZenaTech (Nasdaq: ZENA) (FSE: 49Q) is a technology company specializing in AI drone, Quantum Computing, Drone as a Service (DaaS), and enterprise SaaS solutions for mission-critical business applications. Since 2017, the company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive exceptional operational efficiencies, accuracy and cost savings. The company operates through seven global offices in North America, Europe, Taiwan and UAE, and a growing global partner network.